Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential Lassen MR; Laux VVasc Health Risk Manag 2008[]; 4 (6): 1373-86In Western countries, venous thromboembolism (VTE) is a widespread and serious disorder, with hospital admission rates that appear to be increasing. Current anticoagulant therapies available for the prevention and treatment of VTE have several drawbacks that make them either difficult to manage effectively, due to a need for careful monitoring to control coagulation, or, in the case of parenterally administered agents, inconvenient for long-term use. To address some of these issues, new anticoagulants are in clinical development that can be orally administered and directly target specific factors in the coagulation cascade. This article reviews the rationale behind development of these novel agents and provides a critical appraisal of their clinical potential. In addition, the impact that the introduction of such agents into clinical practice would have is discussed from the patient perspective.|Administration, Oral[MESH]|Benzimidazoles/administration & dosage[MESH]|Blood Coagulation/*drug effects[MESH]|Dabigatran[MESH]|Fibrinolytic Agents/*administration & dosage/adverse effects/history[MESH]|Hemorrhage/chemically induced[MESH]|History, 20th Century[MESH]|History, 21st Century[MESH]|Humans[MESH]|Medication Adherence[MESH]|Morpholines/administration & dosage[MESH]|Pyrazoles/administration & dosage[MESH]|Pyridines/administration & dosage[MESH]|Pyridones/administration & dosage[MESH]|Risk Assessment[MESH]|Rivaroxaban[MESH]|Thiophenes/administration & dosage[MESH]|Treatment Outcome[MESH]|Venous Thromboembolism/blood/*drug therapy[MESH] |
